HUNTINGDON VALLEY, Pa. & CHICAGO--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ-GM:IMMC) will present three podium presentations at the 43rd annual American Society of Clinical Oncology (ASCO), the premier educational and scientific event in the oncology community, June 1-5 at the McCormick Place Convention Complex in Chicago, Illinois. The presentations will discuss clinical trial results discussing circulating tumor cells (CTCs) as reliable predictor of patient survival in metastatic prostate and colorectal cancers applications and how circulating tumor cells expressing the insulin growth factor-1 receptor (IGF-1R) can be leveraged.
